Breath Taking AI
Do you know the true state of your lungs?
More than 800 million people suffer from asthma and chronic obstructive lung disease globally. A large group of patients are undiagnosed or not properly medicated, leading to decreased quality of life, impaired job readiness, and elevated risks of comorbidities and mortality. Many of these patients suffer from occupational respiratory disease, exposure to polluted environments and behaviours such as smoking and vaping. Other at risk groups include women , children and low income communities.
While the number of people impacted by respiratory diseases is increasing, access to healthcare resources is decreasing. There is a global shortage of pulmonologists, technicians and clinicians available to support these patients. The consequence of this gap is an ever increasing time to diagnosis, and hospitalisations resulting in life long disability.
Increasing awareness of sex differences in airway diseases LINK
Study estimates exposure to air pollution increases COVID-19 deaths by 15% worldwide LINK
Indoor air pollution and respiratory health in the elderly LINK
Endocrine regulation of lung disease and inflammation. Link
Menopause Is Associated with Accelerated Lung Function Decline Link
Respiratory disease "prevention as a service"
Eupnoos is on a mission to address inequities in access to care by putting a 'digital pulmonologist' on the smartphone.
Our proprietary AI (patent pending) monitors every individual for symptoms associated with respiratory disease and diagnoses lung disease using sound based digital biomarkers derived from forced exhalation and inhalation (derivative of spirometry*). The aggregated data is analysed by our proprietary AI to provide evidence based recommendations via the app.
We call this 'prevention as a service'.
Pure software solution
Eupnoos is the only purely digital system that measures lung function without any hardware or consumables to diagnose lung disease and to monitor general health. It enable healthcare systems and payers to offer supported self management by monitoring for treatment efficacy, provide virtual lung function testing, rapidly scale inhaler reviews and personalising asthma management plans.
In addition to respiratory diseases, Eupnoos's lung function measurement technology is easily deployed via an API to monitor a range of other conditions such as cardiovascular diseases, ALS and other conditions involving pulmonary function.
Patient-centricty at it's core
Close collaborations with patients and clinicians has helped with the co-development of a digital app that has usability and inclusiveness at its core.
Occupational lung disease screening for every employee
According to the British Lung Foundation , occupational lung disease is a major cause of work-related ill health. It is as a result of exposure to hazardous workplace chemicals, dusts and fumes which result in a wide range of life-threatening or adversely life-changing conditions.
The largest household study of employment circumstances in the UK, the Labour Force Survey, documented the following causes for self-reported cases of breathing or lung problems
Airborne materials from spray painting or manufacturing foam products (in 13% of cases)
Dust from flour, grain/cereal, animal feed or straw (7% of cases)
Airborne materials while welding, soldering, or cutting/grinding metals (10% of cases)
Dust from stone, cement, brick or concrete (nearly 20% of cases)
General work environment e.g. uncomfortable – hot/cold/damp/wet/dry/etc (20% of cases)
*Spirometry (spy-ROM-uh-tree) is a common clinical test used to assess how well your lungs work by measuring how much air you inhale, how much you exhale and how quickly you exhale.
Spirometry is used to diagnose asthma, chronic obstructive pulmonary disease (COPD) and other conditions that affect breathing. Spirometry may also be used periodically to monitor your lung condition and check whether a treatment for a chronic lung condition is helping you breathe better.
(1) Boulet LP, Bourbeau J, Skomro R, Gupta S. Major care gaps in asthma, sleep and chronic obstructive pulmonary disease: a road map for knowledge translation. Can Respir J. 2013;20(4):265-269. doi:10.1155/2013/496923